Federal Policy Shift: White House Signals Potential Approval for 'Natural 7-OH' Kratom, Impacting Product Definitions

No immediate changes to kratom's legal status; however, the White House signals a potential shift towards approving 'natural 7-OH' (trace amounts in plain leaf), which could prevent future federal restrictions. No direct immediate impact on payment processing or bank stability; a more favorable federal stance could reduce long-term risk for kratom businesses. No new shipping or logistics warnings; this clarification may help prevent future federal shipping restrictions on plain leaf kratom products.

President Donald Trump has indicated his administration is seriously considering approving "natural 7-OH," a move that could significantly impact the federal stance on certain kratom products. This statement, made following a White House meeting on drug policy, suggests a potential pivot from a 2025 recommendation by the FDA and HHS to classify 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance. Officials previously clarified that their recommendation targeted 7-OH-dominant products above a concentration threshold, explicitly stating that natural kratom leaf and its trace amounts of 7-OH would not be included. Trump's current remarks are likely in line with this distinction, aiming to keep plain leaf kratom, containing naturally occurring trace amounts of 7-OH, legal. While the DEA has not yet initiated the formal scheduling process for 7-OH, this development signals a potentially more favorable federal regulatory environment for natural kratom products, contrasting with a previous unsuccessful attempt in 2016 to schedule kratom itself. Source: Kratom Science via Sentinel Newsroom

Related